This study investigates the first-line treatment for metastatic pancreatic cancer. The purpose of this study is to evaluate the effectiveness and safety of a specific combination of investigational medications for this condition.
The study evaluates how well the treatment works and its safety for patients. It focuses on understanding the overall effects and potential benefits of the investigational medication in managing the condition.
- Who can participate: Adults aged 18 to 75 years with confirmed pancreatic ductal adenocarcinoma and at least one measurable lesion may participate. Participants should have no prior systematic anti-tumor treatment and meet specific health criteria.
- Study details: Participants will receive a combination treatment that includes an investigational medication.